Liquid biopsy samples need ultrasensitive assays to detect the powerful information they hold
Liquid biopsy collects samples such as blood, urine, saliva and stool and is significantly less intrusive than surgical biopsy. It provides access to cell-free DNA (cfDNA), enabling early detection of cancer cells (before a tumour develops) and together with RNA detects non-shedding cancers. Liquid biopsies allow for an easier and safer mode to monitor disease recurrence, therapeutic selection and effectiveness.
Molecular diagnostic tests are progressively moving towards lyophilized and air-dried formats. Lyo-Ready and Air-Dryable qPCR master mixes are 4x concentrated, glycerol-free and contain specialized excipients that are compatible with lyophilization or air-drying to create ambient-temperature stable assays, or they can be used as a wet mix. They are highly inhibitor-tolerant and ultra-sensitive making them ideal for point-of-care or machine-automated multiplexing assays. As ready-to-use mixes, they require no further optimization besides the addition of primers and probes.
To facilitate biomarker discovery in liquid biopsies, BioCat offers comprehensive tools for the complete workflow from the collection and preservation of blood or urine through the enrichment, purification and NGS analysis of